DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksSchließen
Referenz
Madan A, Zhu YF, Markison S. et al.
SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers.
J Endocr Soc 2019;
3: SAT-429
Für die Inhalte der Internetseiten anderer Anbieter übernehmen wir keine Verantwortung.